1'-{2-(2-trifluoromethylphenoxy)acetyl}spiro(indole-3,4'-piperidine)-2(1H)-one | 1086061-32-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1'-{2-(2-trifluoromethylphenoxy)acetyl}spiro(indole-3,4'-piperidine)-2(1H)-one
• 英文别名: 1'-{2-(2-trifluoromethylphenoxy)acetyl}spiro(indole-3,4'-pi peridine)-2(1H)-one；1'-[2-[2-(trifluoromethyl)phenoxy]acetyl]spiro[1H-indole-3,4'-piperidine]-2-one
• CAS: 1086061-32-6
• 化学式: C₂₁H₁₉F₃N₂O₃
• 分子量: 404.389
• InChiKey: NTUSRVWASYTKOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  tricyclopropylbismuth 、 1'-{2-(2-trifluoromethylphenoxy)acetyl}spiro(indole-3,4'-piperidine)-2(1H)-one 在 吡啶 、 copper diacetate 作用下， 以 二氯甲烷 为溶剂， 反应 14.0h， 以60%的产率得到1-cyclopropyl-1'-{2-(2-trifluoromethylphenoxy)acetyl}spiro(indole-3,4'-piperidine)-2-one
  参考文献：
  名称：

  NOVEL SPIROOXYINDOLE COMPOUNDS AND DRUGS CONTAINING SAME

  摘要：

  本发明的化合物或其盐，或其溶剂化物，由下式（1）表示的螺环氧吲哚化合物，显示出对11β-羟基类固醇脱氢酶的优越抑制作用，并且可用作预防或治疗涉及11β-羟基类固醇脱氢酶的疾病的药剂（特别是糖尿病、胰岛素抵抗、糖尿病并发症、肥胖、血脂异常、高血压、脂肪肝或代谢综合征）。

  公开号：

  US20080306102A1
• 作为产物：
  描述：

  ethyl 2-(2-(trifluoromethyl)phenoxy)acetate 在 N,N-二甲基甲酰胺 sodium hydroxide 、 草酰氯 、 水 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 3.5h， 生成 1'-{2-(2-trifluoromethylphenoxy)acetyl}spiro(indole-3,4'-piperidine)-2(1H)-one
  参考文献：
  名称：

  NOVEL SPIROOXYINDOLE COMPOUNDS AND DRUGS CONTAINING SAME

  摘要：

  本发明的化合物或其盐，或其溶剂化物，由下式（1）表示的螺环氧吲哚化合物，显示出对11β-羟基类固醇脱氢酶的优越抑制作用，并且可用作预防或治疗涉及11β-羟基类固醇脱氢酶的疾病的药剂（特别是糖尿病、胰岛素抵抗、糖尿病并发症、肥胖、血脂异常、高血压、脂肪肝或代谢综合征）。

  公开号：

  US20080306102A1

文献信息

• FXR agonist compositions for combination therapy
  申请人：Intercept Pharmaceuticals, Inc.

  公开号：US10894054B2

  公开（公告）日：2021-01-19

  The present application relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one additional therapeutic agent that lowers the glucose level in the blood, stimulates insulin secretion, and/or increases insulin sensitivity. The present application relates to use of the pharmaceutical composition for the treatment or prevention of a FXR mediated disease or condition, such as NAFLD and NASH, a disease or condition related to an elevated level of glucose in the blood, decreased secretion of insulin, and/or decreased insulin sensitivity such as hyperglycemia, diabetes, obesity, and insulin resistance, or for lowering the glucose level in the blood, stimulating insulin secretion, and/or increasing insulin sensitivity.

  本申请涉及一种药物组合物，其包含一种FXR激动剂和至少一种额外治疗剂的组合，该治疗剂可降低血液中的葡萄糖水平、刺激胰岛素分泌和/或增加胰岛素敏感性。本申请涉及该药物组合物用于治疗或预防FXR介导的疾病或病症，如非酒精性脂肪肝和NASH，与血液中葡萄糖水平升高、胰岛素分泌减少和/或胰岛素敏感性降低有关的疾病或病症，如高血糖、糖尿病、肥胖和胰岛素抵抗，或用于降低血液中葡萄糖水平、刺激胰岛素分泌和/或增加胰岛素敏感性。
• 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF
  申请人：Jacobson Peer B.

  公开号：US20110159005A1

  公开（公告）日：2011-06-30

  A method for treating a patient suffering from inflammation, chronic inflammation, pain, rheumatoid arthritis (RA), osteoarthritis and osteoporosis, comprising administering an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme.
• PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY
  申请人：Intercept Pharmaceuticals, Inc.

  公开号：US20180117065A1

  公开（公告）日：2018-05-03

  The present application relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one additional therapeutic agent that lowers the glucose level in the blood, stimulates insulin secretion, and/or increases insulin sensitivity. The present application relates to use of the pharmaceutical composition for the treatment or prevention of a FXR mediated disease or condition, such as NAFLD and NASH, a disease or condition related to an elevated level of glucose in the blood, decreased secretion of insulin, and/or decreased insulin sensitivity such as hyperglycemia, diabetes, obesity, and insulin resistance, or for lowering the glucose level in the blood, stimulating insulin secretion, and/or increasing insulin sensitivity.
• US8871208B2
  申请人：——

  公开号：US8871208B2

  公开（公告）日：2014-10-28
• [EN] PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY<br/>[FR] COMPOSITIONS PHARMACEUTIQUES POUR THÉRAPIE COMBINÉE
  申请人：INTERCEPT PHARMACEUTICALS INC

  公开号：WO2016164413A1

  公开（公告）日：2016-10-13

  The present application relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one additional therapeutic agent that lowers the glucose level in the blood, stimulates insulin secretion, and/or increases insulin sensitivity. The present application relates to use of the pharmaceutical composition for the treatment or prevention of a FXR mediated disease or condition, such as NAFLD and NASH, a disease or condition related to an elevated level of glucose in the blood, decreased secretion of insulin, and/or decreased insulin sensitivity such as hyperglycemia, diabetes, obesity, and insulin resistance, or for lowering the glucose level in the blood, stimulating insulin secretion, and/or increasing insulin sensitivity.